Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy

Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy

Objectives: The impact of very low-level viremia (VLLV) and low-level viremia (LLV) are rarely investigated among people living with HIV (PLWH) receiving dolutegravir- vs protease inhibitor (PI)-based antiretroviral therapy (ART). Methods: Virally suppressed PLWH receiving long-term PI-containing AR...

Full description

Bibliographic Details
Main Authors: Guan-Jhou Chen, Hsin-Yun Sun, Sui-Yuan Chang, Aristine Cheng, Yu-Shan Huang, Sung-Hsi Huang, Yi-Chia Huang, Yi-Ching Su, Wen-Chun Liu, Chien-Ching Hung
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:International Journal of Infectious Diseases
Subjects:
Integrase strand transfer inhibitor
Nucleoside reverse transcriptase inhibitor
Virological failure
Resistance-associated mutation
Genetic barrier
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221001314

Internet

http://www.sciencedirect.com/science/article/pii/S1201971221001314

Similar Items